Caxton Associates (UK)’s SpringWorks Therapeutics SWTX Stock Holding History

Caxton Associates (UK)’s Portfolio SWTX Stock Details SWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-28,897	Closed	-$1.36M	–	921
2025 Q2	$1.36M	Buy	28,897 +23,849	+472%	+$1.06M	0.03%	263
2025 Q1	$223K	Buy	+5,048	New	+$232K	0.01%	687

Other funds holding SWTX

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Caxton Associates (UK)'s SWTX Position: Q3 2025 in Review

Caxton Associates (UK) sold out of SpringWorks Therapeutics (SWTX) in Q3 2025, closing a stake of 28,897 shares — an estimated $1.36M sold.

Caxton Associates (UK) first reported a position in SWTX in Q1 2025 and held it in 2 quarters. The position peaked at $1.36M in Q2 2025. 3 funds tracked by Wall St. Rank hold SWTX as of Q3 2025.

Caxton Associates (UK) reported no remaining SpringWorks Therapeutics position as of Q3 2025 after selling out during the quarter.
Caxton Associates (UK) sold 28,897 SpringWorks Therapeutics shares in Q3 2025, an estimated $1.36M.
Caxton Associates (UK) first reported a position in SpringWorks Therapeutics in Q1 2025 and held it in 2 quarters.
Caxton Associates (UK)'s SpringWorks Therapeutics position peaked at $1.36M in Q2 2025.
3 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q3 2025.

Based on Caxton Associates (UK)'s 13F filing for Q3 2025, filed 17 Nov 2025.